Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients

Noam Y. Harel; Merit E. Cudkowicz; Robert H. Brown; Stephen M. Strittmatter

doi:10.1080/13547500903056051

Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients

Noam Y. Harel
, Merit E. Cudkowicz
, Robert H. Brown
, Stephen M. Strittmatter

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Improved biomarkers would facilitate the diagnosis and treatment of amyotrophic lateral sclerosis (ALS). Muscle content of the neuritic outgrowth inhibitor Nogo-A is increased in patients with ALS and other denervating conditions. Seeking a less invasive diagnostic method, we sought to determine whether or not Nogo increases in the serum of ALS patients. We developed a dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA) protocol to screen serum samples from 172 ALS patients and 172 healthy controls for Nogo-A immunoreactivity. Unexpectedly, there was a trend toward decreased levels of serum Nogo-A in ALS. Mean serum Nogo-A level in ALS patients was 0.71nM (95% confidence interval (CI) 0.421.00), as opposed to 1.15nM (95% CI 0.721.59) in healthy controls. A significantly larger percentage of healthy control sera (11.0% vs 4.7%) displayed markedly elevated levels of Nogo-A. Additional study is required to determine the factors that lead to elevated Nogo-A levels in a subset of both ALS patients and healthy controls.

Original language	English
Pages (from-to)	414-417
Number of pages	4
Journal	Biomarkers
Volume	14
Issue number	6
DOIs	https://doi.org/10.1080/13547500903056051
State	Published - Sep 2009
Externally published	Yes

Keywords

ALS
Biomarker
DELFIA
ELISA
Nogo-A

Access to Document

10.1080/13547500903056051

Cite this

@article{949385c21cc64a2baa43fa5d11d13b31,

title = "Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients",

abstract = "Improved biomarkers would facilitate the diagnosis and treatment of amyotrophic lateral sclerosis (ALS). Muscle content of the neuritic outgrowth inhibitor Nogo-A is increased in patients with ALS and other denervating conditions. Seeking a less invasive diagnostic method, we sought to determine whether or not Nogo increases in the serum of ALS patients. We developed a dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA) protocol to screen serum samples from 172 ALS patients and 172 healthy controls for Nogo-A immunoreactivity. Unexpectedly, there was a trend toward decreased levels of serum Nogo-A in ALS. Mean serum Nogo-A level in ALS patients was 0.71nM (95\% confidence interval (CI) 0.421.00), as opposed to 1.15nM (95\% CI 0.721.59) in healthy controls. A significantly larger percentage of healthy control sera (11.0\% vs 4.7\%) displayed markedly elevated levels of Nogo-A. Additional study is required to determine the factors that lead to elevated Nogo-A levels in a subset of both ALS patients and healthy controls.",

keywords = "ALS, Biomarker, DELFIA, ELISA, Nogo-A",

author = "Harel, \{Noam Y.\} and Cudkowicz, \{Merit E.\} and Brown, \{Robert H.\} and Strittmatter, \{Stephen M.\}",

note = "Funding Information: We thank Zhengrong Hao and William C. Sessa for sharing their Nogo-B ELISA protocol, and Galen-Royce-Nagel and Patrick Butsch for assistance in obtaining serum samples. We thank the reviewers for excellent comments and suggestions. This work was supported by grants from the NINDS (K08 NS056212), the Falk Medical Research Trust, and the ALS Association. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health. N.Y.H. and S.M.S. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All the authors certify that no financial conflicts of interest relative to this manuscript are present.",

year = "2009",

month = sep,

doi = "10.1080/13547500903056051",

language = "English",

volume = "14",

pages = "414--417",

journal = "Biomarkers",

issn = "1354-750X",

publisher = "Taylor and Francis Ltd.",

number = "6",

}

TY - JOUR

T1 - Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients

AU - Harel, Noam Y.

AU - Cudkowicz, Merit E.

AU - Brown, Robert H.

AU - Strittmatter, Stephen M.

N1 - Funding Information: We thank Zhengrong Hao and William C. Sessa for sharing their Nogo-B ELISA protocol, and Galen-Royce-Nagel and Patrick Butsch for assistance in obtaining serum samples. We thank the reviewers for excellent comments and suggestions. This work was supported by grants from the NINDS (K08 NS056212), the Falk Medical Research Trust, and the ALS Association. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health. N.Y.H. and S.M.S. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All the authors certify that no financial conflicts of interest relative to this manuscript are present.

PY - 2009/9

Y1 - 2009/9

N2 - Improved biomarkers would facilitate the diagnosis and treatment of amyotrophic lateral sclerosis (ALS). Muscle content of the neuritic outgrowth inhibitor Nogo-A is increased in patients with ALS and other denervating conditions. Seeking a less invasive diagnostic method, we sought to determine whether or not Nogo increases in the serum of ALS patients. We developed a dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA) protocol to screen serum samples from 172 ALS patients and 172 healthy controls for Nogo-A immunoreactivity. Unexpectedly, there was a trend toward decreased levels of serum Nogo-A in ALS. Mean serum Nogo-A level in ALS patients was 0.71nM (95% confidence interval (CI) 0.421.00), as opposed to 1.15nM (95% CI 0.721.59) in healthy controls. A significantly larger percentage of healthy control sera (11.0% vs 4.7%) displayed markedly elevated levels of Nogo-A. Additional study is required to determine the factors that lead to elevated Nogo-A levels in a subset of both ALS patients and healthy controls.

AB - Improved biomarkers would facilitate the diagnosis and treatment of amyotrophic lateral sclerosis (ALS). Muscle content of the neuritic outgrowth inhibitor Nogo-A is increased in patients with ALS and other denervating conditions. Seeking a less invasive diagnostic method, we sought to determine whether or not Nogo increases in the serum of ALS patients. We developed a dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA) protocol to screen serum samples from 172 ALS patients and 172 healthy controls for Nogo-A immunoreactivity. Unexpectedly, there was a trend toward decreased levels of serum Nogo-A in ALS. Mean serum Nogo-A level in ALS patients was 0.71nM (95% confidence interval (CI) 0.421.00), as opposed to 1.15nM (95% CI 0.721.59) in healthy controls. A significantly larger percentage of healthy control sera (11.0% vs 4.7%) displayed markedly elevated levels of Nogo-A. Additional study is required to determine the factors that lead to elevated Nogo-A levels in a subset of both ALS patients and healthy controls.

KW - ALS

KW - Biomarker

KW - DELFIA

KW - ELISA

KW - Nogo-A

UR - https://www.scopus.com/pages/publications/70849084880

U2 - 10.1080/13547500903056051

DO - 10.1080/13547500903056051

M3 - Article

C2 - 19548774

AN - SCOPUS:70849084880

SN - 1354-750X

VL - 14

SP - 414

EP - 417

JO - Biomarkers

JF - Biomarkers

IS - 6

ER -

Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients

Abstract

Keywords

Access to Document

Fingerprint

Cite this